Next Generation Antibody Drug Market Report 2026

Next Generation Antibody Drug Market Overview

• Next Generation Antibody Drug market size has reached to $16.4 billion in 2025 • Expected to grow to $33.53 billion in 2030 at a compound annual growth rate (CAGR) of 15.4% • Growth Driver: Rising Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Sequencing • Market Trend: Innovation In Antibody-Drug Conjugates Advancing Targeted Cancer Therapies And Treatment Efficacy • North America was the largest region in 2025.

What Is Covered Under Next Generation Antibody Drug Market?

Next-generation antibody drugs refer to advanced therapeutic antibodies designed to target specific antigens with higher precision and efficacy, often incorporating innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to improve disease treatment outcomes by enhancing targeting capabilities and minimizing side effects. The main product types of next-generation antibody drugs are monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and other types. Monoclonal antibodies are identical copies of a single antibody, created by cloning a unique immune cell, and are used to treat various conditions such as cancer and autoimmune disorders. Their mechanisms of action encompass checkpoint inhibitors, immune modulators, receptor blockers, targeted cytotoxic agents, and neutralizing antibodies. Delivery methods for these drugs include intravenous (IV), subcutaneous, intramuscular administration, oral formulations, and transdermal delivery systems. The various applications include oncology, autoimmune diseases, infectious diseases, and others and are used by several end users, such as hospitals, research institutes, specialty clinics, and other healthcare providers.

What Is The Next Generation Antibody Drug Market Growth Forecast?

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $33.53 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing demand for targeted biologics, advancements in conjugation technologies, expansion of autoimmune disease treatments, rising oncology drug pipelines. Major trends in the forecast period include rapid development of bispecific antibodies, increasing adoption of antibody-drug conjugates, growing focus on precision targeted therapies, expansion of antibody applications beyond oncology, rising clinical trials for advanced antibody platforms.

Global Next Generation Antibody Drug Market Segmentation

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types 2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies 3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration 4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications 5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users Subsegments: 1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies 2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies 3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

What Is The Driver Of The Next Generation Antibody Drug Market?

The increasing focus on personalized medicine is expected to propel the growth of the next-generation antibody-drug market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare strategies to individual patients based on their genetic, environmental, and lifestyle factors, ensuring more effective and targeted therapies. Personalized medicine is rising due to advancements in genomic sequencing, which enable more precise diagnosis and targeted treatment strategies. Next-generation antibody drugs help increase the focus on personalized medicine by allowing the development of targeted therapies customized to individual patients' genetic profiles and disease characteristics, improving efficacy and minimizing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization promoting the adoption of personalized medicine, in 2023, the United States Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, increasing focus on personalized medicine drives the next-generation antibody drug market.

Key Players In The Global Next Generation Antibody Drug Market

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Global Next Generation Antibody Drug Market Trends and Insights

Major companies operating in the next generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates, to enhance targeted cancer therapies, improve therapeutic efficacy, and reduce systemic toxicity. An antibody-drug conjugate (ADC) is a targeted cancer therapy that combines a monoclonal antibody with a cytotoxic drug via a linker to selectively deliver the drug to tumor cells while minimizing damage to healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology company, partnered with Duality Biologics (Suzhou) Co. Ltd., a China-based pharmaceutical company, and received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for their next-generation antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, aimed at treating platinum-resistant ovarian cancer. The drug utilizes DualityBio's innovative DITAC (Duality Immune Toxin Antibody Conjugates) platform, which combines a highly potent cytotoxic payload with a monoclonal antibody, enabling precision in delivering treatment directly to cancer cells. BNT325/DB-1305's ability to precisely target cancer cells while minimizing damage to healthy tissues stands out as a key advantage in enhancing treatment efficacy and reducing side effects.

What Are Latest Mergers And Acquisitions In The Next Generation Antibody Drug Market?

In March 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed amount. With this acquisition, Johnson and Johnson aims to advance its oncology portfolio by developing innovative, targeted antibody-drug conjugates that improve treatment outcomes and reduce side effects for patients with difficult-to-treat cancers. Ambrx Biopharma Inc. is a US-based company dedicated to advancing the development of next-generation antibody-drug conjugates (ADCs).

Regional Insights

North America was the largest region in the next generation antibody drug market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next Generation Antibody Drug Market?

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Next Generation Antibody Drug Market Report 2026?

The next generation antibody drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next generation antibody drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.